A cost-effectiveness analysis of neonatal ECMO using existing evidence

S Howard; M Mugford; C Normand; D Elbourne; A Grant; D Field; A Johnson

doi:10.1017/s0266462300009417

A cost-effectiveness analysis of neonatal ECMO using existing evidence

Int J Technol Assess Health Care. 1996 Winter;12(1):80-92. doi: 10.1017/s0266462300009417.

Authors

S Howard¹, M Mugford, C Normand, D Elbourne, A Grant, D Field, A Johnson

Affiliation

¹ London School of Hygiene and Tropical Medicine.

PMID: 8690565
DOI: 10.1017/s0266462300009417

Abstract

A cost-effectiveness analysis is part of the U.K. ECMO Trial. In preparation for this analysis, existing evidence on the costs and effectiveness of neonatal ECMO was evaluated. ECMO appears to be more costly but may be more or less effective than conventional treatment. No case can be made for introducing ECMO before trial results are available.

Publication types

Clinical Trial
Meta-Analysis
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Cost-Benefit Analysis
Decision Support Techniques
England
Extracorporeal Membrane Oxygenation / economics*
Health Planning
Humans
Infant, Newborn
Intensive Care, Neonatal
Respiratory Insufficiency / economics
Respiratory Insufficiency / mortality
Respiratory Insufficiency / therapy*
Scotland
Technology Assessment, Biomedical*
Treatment Outcome